By Fineline Cube Changchun High & New Technology Industry (Group) Inc. (SHE: 000661) announced that China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for GenSci148 injection, developed by its subsidiary Changchun Genescience Pharmaceutical Co., Ltd. (“GenSci”). The Class 1 therapeutic biological product targets three major retinal vascular diseases: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Development Milestone & Product Profile
| Parameter | Detail |
|---|---|
| Developer | Changchun Genescience Pharmaceutical Co., Ltd. (GenSci) |
| Parent Company | Changchun High & New Technology Industry (Group) Inc. (SHE: 000661) |
| Regulatory Status | IND accepted by NMPA |
| Product Classification | Class 1 therapeutic biological product |
| Indications | nAMD, DME, RVO |
| Technology Platform | Proprietary ProlonX long-acting platform |
Mechanism of Action & Therapeutic Innovation
Multi-Target Binding Profile
- VEGF Family: Simultaneously binds VEGF-A, VEGF-C, and VEGF-D
- Angiopoietin Pathway: Blocks Ang-2 and inhibits Ang-2-Tie2 signaling pathway
- Dual Pathway Inhibition: First-in-class approach targeting both VEGF and angiopoietin pathways simultaneously
Clinical Advantages
- Enhanced Efficacy: Synergistic inhibition of pathological angiogenesis through multi-target blockade
- Improved Vascular Stability: Dual pathway targeting reduces vascular permeability and enhances vessel integrity
- Extended Dosing Intervals: ProlonX long-acting platform enables less frequent administration
- Reduced Treatment Burden: Addresses key limitation of current anti-VEGF monotherapies requiring monthly injections
Market Opportunity & Competitive Landscape
The global retinal vascular disease market represents approximately $15 billion annually, with anti-VEGF therapies dominating current treatment paradigms. However, significant unmet needs remain:
Current Market Limitations
- Treatment Burden: Monthly or bi-monthly intravitreal injections create patient compliance challenges
- Incomplete Response: Up to 30% of patients show suboptimal response to VEGF-A monotherapy
- Disease Progression: Persistent fluid and vision loss despite regular anti-VEGF treatment
GenSci148 Competitive Positioning
- First Multi-Target Approach: Only candidate simultaneously targeting VEGF family + Ang-2 pathway in Chinese development pipeline
- Domestic Innovation Leadership: Represents China’s advancement in complex biologic therapeutics for ophthalmology
- Platform Technology Validation: ProlonX platform could enable future pipeline expansion across multiple indications
Strategic Implications for Changchun High & New Technology
This IND acceptance marks a significant milestone for the company’s transition from traditional pharmaceutical manufacturing to innovative biologics development. GenSci148 represents one of the most advanced ophthalmology assets in China’s domestic pipeline, positioning Changchun High & New Technology to potentially capture substantial market share in the high-value retinal disease segment.
The company’s vertical integration strategy—combining proprietary platform technology, in-house development capabilities, and established commercial infrastructure—provides competitive advantages in development speed, cost efficiency, and eventual market access.
Development Timeline & Next Steps
- Q3-Q4 2026: Initiate Phase 1 clinical trials in China
- 2027: Complete Phase 1 safety and dosing studies; initiate Phase 2 proof-of-concept trials
- 2028-2029: Advance to Phase 3 pivotal trials across all three indications
- 2030+: Potential NDA submission and commercial launch
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory milestones, clinical development timelines, and market opportunities. Actual results may differ materially due to clinical trial outcomes, regulatory requirements, competitive developments, and other risk factors inherent in pharmaceutical development.-Fineline Info & Tech